ClinicalTrials.gg
CompletedNCT00811252Updated Jan 29, 2014Results posted

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-01-29.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
24th of 54
453 · median 413
Started
2009
the only one that year
Phase 3
31 of 54
1 open now
Registered
9th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 24th largest by enrollment, is the only one that started in 2009, is one of 31 in phase 3, and was the 9th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of double-blind treatment in elderly patients.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Elderly
  • Acute treatment
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical Diagnosis of recurrent Major Depressive Episode (MDE) according the , 4th Edition, Text Revision (DSM-IV-TR) criteria with:

  • Reported duration of the current episode of at least 4 weeks
  • MADRS total score >=26
  • At least one previous MDE before the age of 60 years

Exclusion criteria

Exclusion Criteria:

  • (MMSE) \<24
  • Any current anxiety disorder as defined in the
  • Current or past history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR
  • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR
  • Presence or history of a neurological disorder (including epilepsy)
  • Neurodegenerative disorder (Alzheimer's disease, Parkinson disease, multiple sclerosis, Huntington disease, etc)
  • Any Axis II disorder that might compromise the study
  • Significant risk of suicide according to the investigator's opinion, or has a score >=5 on item 10 of the MADRS or has made a suicide attempt in the previous 6 months

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
453 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Vortioxetine 5 mg

    Drug: Vortioxetine (Lu AA21004)

  • Other
    Duloxetine 60 mg

    Active reference

    Drug: Duloxetine

Interventions

  • DrugPlacebo

    capsules; daily; orally

  • encapsulated tablets; daily; orally

    Also known as: Brintellix

  • encapsulated tablets; daily; orally

    Also known as: Cymbalta®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment

    The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment

    Time frame: Baseline and Week 6

  2. Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment

    Time frame: Baseline and Week 4

  3. Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment

    Time frame: Baseline and Week 2

  4. Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment

    Time frame: Baseline and Week 1

  5. Change From Baseline in MADRS Total Score After 8 Weeks of Treatment

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 8

  6. Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment

    The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

    Time frame: Baseline and Week 8

  7. Change From Baseline in CGI-S Score After 8 Weeks of Treatment

    The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

    Time frame: Baseline and Week 8

  8. Change in Clinical Status Using CGI-I Score at Week 8

    The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

    Time frame: Week 8

  9. Change From Baseline in GDS Total Score After 8 Weeks of Treatment

    The Geriatric Depression Scale (GDS) is a patient self-rating scale designed for the screening of depression in the elderly. It has also been validated as a measure of depression severity. The original version consists of 30 questions with a yes/no answer. In this study, the short 15-item version was used. The total score ranges from 0 to 15, with 15 representing maximum severity.

    Time frame: Baseline and Week 8

  10. Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)

    Time frame: Week 8

  11. Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)

    Time frame: Week 8

  12. Risk of Suicidality Using C-SSRS Scores

    The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with sub-questions that assess severity. The tool was administered via an interview with the patient.

    Time frame: Up to 8 weeks

07

Results

Posted Dec 18, 2013

Participant flow

Patients were mainly recruited via psychiatric, psycho-geriatric, and geriatric inpatient or outpatient settings.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 5 mgDuloxetine 60 mg
Started145156151
Completed128136128
Not completed172023
Withdrew: Adverse event61015
Withdrew: Lack of efficacy720
Withdrew: Protocol violation332
Withdrew: Withdrawal of consent122
Withdrew: Lost to follow-up002
Withdrew: Administrative or other reasons032

Outcome measures

PrimaryChange From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment-10.3 ± 0.76-13.7 ± 0.74-15.8 ± 0.75
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.0011 (Since p-value \<0.05, hierarchically testing continued) · Mean difference (final values): -3.32 · 95% CI -5.31 to -1.34A statistical testing strategy was defined a priori for a single dose of vortioxetine that was tested versus placebo in the primary and key secondary efficacy analyses.
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -5.48 · 95% CI -7.50 to -3.46
SecondaryChange From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment
Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment-10.2 ± 0.71-12.3 ± 0.69-14.4 ± 0.70
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.0240 (Since p-value \<0.05, hierarchically testing continued) · Mean difference (final values): -2.13 · 95% CI -3.98 to -0.28A statistical testing strategy was defined a priori for a single dose of vortioxetine that was tested versus placebo in the primary and key secondary efficacy analyses.
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -4.22 · 95% CI -6.10 to -2.34
SecondaryChange From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment
Time frame:
Baseline and Week 4
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment-8.99 ± 0.64-10.1 ± 0.62-12.3 ± 0.63
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.2134 (Since p-value \>0.05, hierarchically testing stopped here.) · Mean difference (final values): -1.06 · 95% CI -2.72 to 0.61
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = 0.0002 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -3.30 · 95% CI -4.99 to -1.60
SecondaryChange From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment
Time frame:
Baseline and Week 2
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment-6.66 ± 0.53-6.95 ± 0.51-7.91 ± 0.52
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.6879 (A nominal p-value is provided.) · Mean difference (final values): -0.28 · 95% CI -1.67 to 1.10
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = 0.0827 (A nominal p-value is provided.) · Mean difference (final values): -1.25 · 95% CI -2.65 to 0.16
SecondaryChange From Baseline in HAM-D-24 Total Score After 1 Week of Treatment
Time frame:
Baseline and Week 1
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment-3.62 ± 0.41-4.04 ± 0.40-3.48 ± 0.41
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.4482 (A nominal p-value is provided.) · Mean difference (final values): -0.42 · 95% CI -1.49 to 0.66
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = 0.7971 (A nominal p-value is provided.) · Mean difference (final values): 0.14 · 95% CI -0.95 to 1.24
SecondaryChange From Baseline in MADRS Total Score After 8 Weeks of Treatment

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment-11.2 ± 0.77-15.5 ± 0.75-18.0 ± 0.76
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = <0.0001 (A nominal p-value is provided. No correction for multiplicity was made.) · Mean difference (final values): -4.29 · 95% CI -6.32 to -2.26
SecondaryChange From Baseline in HAM-A Total Score After 8 Weeks of Treatment

The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment-5.74 ± 0.55-8.09 ± 0.54-9.28 ± 0.54
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.0015 (A nominal p-value is provided. No correction for multiplicity was made.) · Mean difference (final values): -2.35 · 95% CI -3.80 to -0.91
SecondaryChange From Baseline in CGI-S Score After 8 Weeks of Treatment

The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in CGI-S Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in CGI-S Score After 8 Weeks of Treatment-1.03 ± 0.11-1.63 ± 0.10-2.05 ± 0.11
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = <0.0001 (A nominal p-value is provided. No correction for multiplicity was made.) · Mean difference (final values): -0.60 · 95% CI -0.88 to -0.32
SecondaryChange in Clinical Status Using CGI-I Score at Week 8

The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change in Clinical Status Using CGI-I Score at Week 8
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change in Clinical Status Using CGI-I Score at Week 82.91 ± 0.102.35 ± 0.092.07 ± 0.10
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = <0.0001 (A nominal p-value is provided. No correction for multiplicity was made.) · Mean difference (final values): -0.56 · 95% CI -0.82 to -0.31
SecondaryChange From Baseline in GDS Total Score After 8 Weeks of Treatment

The Geriatric Depression Scale (GDS) is a patient self-rating scale designed for the screening of depression in the elderly. It has also been validated as a measure of depression severity. The original version consists of 30 questions with a yes/no answer. In this study, the short 15-item version was used. The total score ranges from 0 to 15, with 15 representing maximum severity.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in GDS Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in GDS Total Score After 8 Weeks of Treatment-0.65 ± 0.17-1.08 ± 0.17-1.32 ± 0.17
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.0552 (A nominal p-value is provided. No correction for multiplicity was made.) · Mean difference (final values): -0.44 · 95% CI -0.88 to 0.01
SecondaryProportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)
Time frame:
Week 8
Reported as:
Number · percentage of patients
Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)
percentage of patientsPlaceboVortioxetine 5 mgDuloxetine 60 mg
Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)355363
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = 0.0008 (A nominal p-value is provided. No correction for multiplicity was made.) · Odds ratio (or): 0.43 · 95% CI 0.26 to 0.70
SecondaryProportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
Time frame:
Week 8
Reported as:
Number · percentage of patients
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
percentage of patientsPlaceboVortioxetine 5 mgDuloxetine 60 mg
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)213447
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = 0.0090 (A nominal p-value is provided. No correction for multiplicity was made.) · Odds ratio (or): 0.47 · 95% CI 0.27 to 0.83
SecondaryRisk of Suicidality Using C-SSRS Scores

The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with sub-questions that assess severity. The tool was administered via an interview with the patient.

Time frame:
Up to 8 weeks
Reported as:
Number · participants
Risk of Suicidality Using C-SSRS Scores
participantsPlaceboVortioxetine 5 mgDuloxetine 60 mg
No ideation or behavior103107106
Completed Suicide000
Suicide Attempt001
Preparatory Actions Toward Imminent Suicidal Behav000
Suicidal Ideation: Passive8147
Suicidal Ideation: Active / Nonspecific300
Suicidal Ideation: Active / Method, but no intent000
Suicidal Ideation: Active / Method and intent, but000
Suicidal Ideation: Active / Method, intent, and pl000
Self-Injurious Behavior Without Suicidal Intent000

Adverse events

Collected over Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/145 (2.8%)63/145 (43.4%)
Vortioxetine 5 mg—1/156 (0.6%)72/156 (46.2%)
Duloxetine 60 mg—1/151 (0.7%)104/151 (68.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 5 mgDuloxetine 60 mg
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/550/491/51
Hip fractureInjury, poisoning and procedural complications1/1450/1560/151
Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1450/1560/151
Transient ischaemic attackNervous system disorders1/1450/1560/151
DepressionPsychiatric disorders1/1450/1560/151
Major depressionPsychiatric disorders0/1451/1560/151
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboVortioxetine 5 mgDuloxetine 60 mg
NauseaGastrointestinal disorders12/14534/15650/151
Dry mouthGastrointestinal disorders7/14510/15633/151
HeadacheNervous system disorders25/14518/15618/151
ConstipationGastrointestinal disorders6/14510/15621/151
FatigueGeneral disorders5/14511/15616/151
SomnolenceNervous system disorders3/1454/15616/151
HyperhidrosisSkin and subcutaneous tissue disorders4/1456/15616/151
DiarrhoeaGastrointestinal disorders10/1458/15614/151
DizzinessNervous system disorders10/14514/15614/151
Ejaculation delayedReproductive system and breast disorders0/550/493/51

Baseline characteristics

Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid post-baseline assessment of the primary efficacy variable

Age, Continuous
Age, Continuous(years)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean70.3 ± 4.470.5 ± 4.870.9 ± 5.570.6 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Female90107100297
Male554951155
HAM-D-24
HAM-D-24(units on a scale)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean29.4 ± 5.129.2 ± 5.028.5 ± 4.929.0 ± 5.0
MADRS
MADRS(units on a scale)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean30.3 ± 3.230.7 ± 3.630.4 ± 3.130.5 ± 3.3
HAM-A
HAM-A(units on a scale)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean19.5 ± 5.719.9 ± 5.819.2 ± 6.519.5 ± 6.0
CGI-S
CGI-S(units on a scale)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean4.7 ± 0.74.8 ± 0.74.7 ± 0.84.7 ± 0.7
GDS
GDS(units on a scale)PlaceboVortioxetine 5 mgDuloxetine 60 mgTotal
Mean7.7 ± 2.07.4 ± 2.27.7 ± 2.37.6 ± 2.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012 Jul;27(4):215-23. doi: 10.1097/YIC.0b013e3283542457. PubMed 22572889 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Feb 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2008
First posted
Dec 18, 2008
Start
Jan 2009
Primary completionActual
Feb 2010
CompletionActual
Mar 2010
Results first posted
Dec 18, 2013
Last update
Jan 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00811252
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 18, 2008
Start date
Jan 2009
Primary completion
Feb 2010
Completion
Mar 2010
Results posted
Dec 18, 2013
Last update
Jan 29, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion